title: A comprehensive patents review on cannabinoid 1 receptor antagonists as antiobesity agents.
abstract: BACKGROUND
  Obesity is a rapidly expanding worldwide health problem. Various targets are investigated presently for the treatment of obesity, but there remains an unmet need for an effective drug therapy with acceptable efficacy levels and reduced side effects. Targeting peripherally located cannabinoid 1 (CB1) receptors is an attractive strategy as these receptors play a vital role in energy homeostasis.
  
  
  METHODS
  CB1 receptor antagonists constitute one of the most important categories of compounds of interest for the control of obesity. In this review, the authors focus on recent advances (since 2007) in diverse chemical classes of patented compounds belonging to the category of CB1 receptor antagonists.
  
  
  CONCLUSIONS
  Safer CB1 receptor antagonists for the treatment of obesity can be discovered by developing such compounds that act peripherally. Increasing the polar service area, decreasing the lipophilicity and designing of neutral antagonists and allosteric inhibitors are some interesting strategies that could offer promising results.
authors.affiliation: a The M. S. University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan Vadodara - 390 001, India mryadav11@yahoo.co.in.
authors.forename: Mayank Kumar
authors.initials: MK
authors.lastname: Sharma
authors.affiliation: a The M. S. University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan Vadodara - 390 001, India mryadav11@yahoo.co.in.
authors.forename: Prashant R
authors.initials: PR
authors.lastname: Murumkar
authors.affiliation: a The M. S. University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan Vadodara - 390 001, India mryadav11@yahoo.co.in.
authors.forename: Mahesh A
authors.initials: MA
authors.lastname: Barmade
authors.affiliation: a The M. S. University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan Vadodara - 390 001, India mryadav11@yahoo.co.in.
authors.forename: Rajani
authors.initials: R
authors.lastname: Giridhar
authors.affiliation: a The M. S. University of Baroda, Pharmacy Department, Faculty of Technology and Engineering, Kalabhavan Vadodara - 390 001, India mryadav11@yahoo.co.in.
authors.forename: Mange Ram
authors.initials: MR
authors.lastname: Yadav
mesh_terms: D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology*; D063387:Cannabinoid Receptor Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D009765:Obesity / Q000188:drug therapy / Q000503:physiopathology; D010330:Patents as Topic; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors* / Q000378:metabolism
chemical_list: D019440:Anti-Obesity Agents; D063387:Cannabinoid Receptor Antagonists; D043884:Receptor, Cannabinoid, CB1
keywords: CB1 receptor antagonists; cannabinoid; endocannabinoid system; obesity; peripherally acting; rimonabant